Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 193 clinical trials
Predictive Clinical and Biological Parameters in Acute Leukemia Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome

remission
bone marrow procedure
myelodysplastic syndromes
leukemia
myeloproliferative disorder
  • 13 views
  • 22 Jan, 2021
  • 1 location
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients. Hence, investigator propose a prospective randomized study to …

essential thrombocythemia
aspirin
thrombosis
hydroxyurea
thrombocytosis
  • 1 views
  • 21 Jan, 2021
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF

anemia
bilateral oophorectomy
vasectomy
cancer
  • 0 views
  • 13 Jun, 2021
  • 158 locations
An Open-Label Multicenter Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive KRT+232 with LDAC or KRT-232 with

cytarabine
cancer
refractory acute myeloid leukemia (aml)
decitabine
  • 2 views
  • 27 Jan, 2021
  • 27 locations
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion

polycythemia
blood transfusion
erythropoietin
luspatercept
myeloproliferative disorder
  • 384 views
  • 07 May, 2021
  • 26 locations
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed/refractory BPDCN …

flow cytometry
chronic myelomonocytic leukemia
acute promyelocytic leukemia
leukemia
refractory acute myeloid leukemia (aml)
  • 322 views
  • 31 May, 2021
  • 20 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 or IDH2-mutant advanced hematologic malignancies who have received standard therapy

hematologic malignancy
IDH2
blast cells
  • 0 views
  • 13 Jun, 2021
  • 17 locations
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the …

luspatercept
growth factor
hysterectomy
cancer
ace-536
  • 82 views
  • 27 Jan, 2021
  • 125 locations
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative

myelofibrosis
ruxolitinib
myelodysplastic syndromes
leukemia
janus kinase inhibitor
  • 242 views
  • 04 Feb, 2021
  • 59 locations
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by …

bone marrow procedure
leukemia
transient myeloproliferative disorder
cytarabine
myeloproliferative disorder
  • 153 views
  • 31 May, 2021
  • 142 locations